• linkedin
  • Increase Font
  • Sharebar

    New Products: FDA approves treatment for complicated UTI

     

    Guidance by GenomeDx

     

    Agreement reached for distribution of UTI, prostatitis tests

    GenomeDx Biosciences and Pathnostics recently announced a strategic agreement for GenomeDx’s distribution of Pathnostics’ Guidance UGx and Guidance PRx, which are commercially available molecular diagnostic tests for urinary tract infections (UTIs) and prostatitis, respectively. GenomeDx will have exclusive distribution rights for Guidance UGx and Guidance PRx in most of the U.S. urology market, and Pathnostics will perform the testing at its CAP-accredited, CLIA-certified laboratory in Irvine, CA. Guidance UGx detects 25 microbial organisms associated with UTIs and determines the susceptibility of the infection to antibiotics considered for treatment. Guidance PRx detects 27 microbial organisms associated with acute prostatitis or chronic bacterial prostatitis and determines the susceptibility of the infection to antibiotics considered for treatment.

    For more information, go to www.genomedx.com/.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll